Dr. Schaider Discusses Drug Resistance for Melanoma

Helmut Schaider, MD
Published: Tuesday, Oct 24, 2017



Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

According to Schaider, adaptive drug resistance occurs at the beginning of treatment. Drug resistance generally occurs in the first 3 to 6 weeks.

More studies need to be conducted to determine why the cells become resistant to certain treatments, states Schaider.
 


Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

According to Schaider, adaptive drug resistance occurs at the beginning of treatment. Drug resistance generally occurs in the first 3 to 6 weeks.

More studies need to be conducted to determine why the cells become resistant to certain treatments, states Schaider.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x